News

Dalila, Janaarthan, Siv and Eystein at the lab

Team changes – July 2023

It was a summer of exciting team changes for our group. We welcomed four new members to the team! We’re all happy to see the team growing again, and really looking forward to working together! 😊

Dalila Sabrine Hedhili started as our newest Research Intern, working with Shiva on the CARMIL-2 deficiency project by immunophenotyping T-cells using flow cytometry as well as getting hands-on experience in CRISPR-Cas9 gene editing technology. Dalila has a BSc degree in Biotechnology from Higher Institute of Biotechnology of Sidi Thabet in Tunisia and an MSc degree in Biology from University of Geneva in Switzerland.

3 Master Students also joined:

Janaarthan Ganeshan’s work involves developing an epegRNA screening platform for primary immunodeficiency mutations in HEK293 cells and Hematopoietic Stem and Progenitor Cells (HSPCs), focusing on optimizing a clinically compatible epegRNA selection pipeline. Janaarthan is currently doing his Master’s degree in Biotechnology at the Norwegian University of Science and Technology, and has a Bachelor’s (Hons) in Biotechnology from Nilai University, Malaysia.

Siv Skundberg Jensen’s work includes trying to correct a Signal Transducer and Activator of Transcription 1 (STAT1) gain-of-function mutation in a patient’s T cells by applying the CRISPR-Cas9 technology. Siv has a Bachelor’s degree in Biomedical Laboratory Sciences from OsloMet, and is now attending a Masters program there.

Eystein Lie Asdal’s main project involves working on testing the feasibility of BAR-Seq in gene-edited T-cells. Eystein has a Bachelor’s degree in Biotechnology from the University of Tromsø, and is currently taking a Master’s degree in Biotechnology at NMBU.

You can see the profiles of the current team and alumni on our Team page.

Latest news

We have a post-doc position currently open, focusing on single-cell sequencing of the CRISPR-corrected cells.
Kata went to American Society of Gene and Cell Therapy (ASGCT) conference in Baltimore, which focuses on novel translational findings in the field.
We had the pleasure of attending the 41st NSI Annual Meeting on November 24th, 2023!
We're excited to present our newest publication, published in the STAR Protocols journal in December 2023.
His lecture was titled “Kurativ behandling av monogenetiske sykdommer med genterapi. En ny tidsalder?” (Curative treatment of monogenetic diseases with gene therapy. A new age?).